IP Library › Granted Patent US 12,584,841
Granted Patent B2
US 12,584,841 · App. 17/537,979 · Granted Mar 24, 2026

Systems and processes for detecting aerosolized viral loads

Inventors: Biplab Pal (Ellicot City, MD); Conrad Bessemer (Millersville, MD)
Assignee: Opteev Technologies, Inc.
G01N15/0656G01N15/0618G01N27/04G01N33/497
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,584,841
App. No.
17/537,979
Granted
Mar 24, 2026
Kind
B2
Abstract

Systems for detecting aerosolized viral loads in an airspace include a first and, optionally, a second volume of a liquid. The first volume includes particles sampled from the airspace, and the second volume is free of virus particles. A first conductivity probe is immersed in the first liquid, and a second conductivity probe is immersed in the second liquid. An alternating voltage is applied to each of the first and second conductivity probes. The difference between the resulting alternating currents through the first and second conductivity probes is determined, and is used to estimate the viral load in the first volume, and in the airspace.

Claims (36)

1 . A process for detecting the presence of a viral load in an airspace, comprising:

providing a solvent;

obtaining an air sample from the airspace;

separating particles from the air sample so that the particles become suspended in the solvent to form a medium;

immersing at least a portion of a conductivity probe in the medium;

applying an alternating voltage to the conductivity probe; and

determining a viral load in the medium based on a frequency response of the conductivity probe to the alternating voltage applied thereto.

2 . The process of claim 1 , wherein determining a viral load in the medium based on a frequency response of the conductivity probe to the alternating voltage applied thereto comprises determining the viral load in the medium based on a correlation between the frequency response of the conductivity probe to the alternating voltage applied thereto, and the viral load.

3 . The process of claim 1 , wherein providing a solvent comprises selecting the solvent from a class of materials capable of acting as a base of a colloidal suspension in which the particles are suspended after being separated from the airspace, and further capable of effecting a transfer of charge between the particles and the solvent.

4 . The process of claim 1 , further comprising reducing or eliminating false positives and false negatives in the viral load determination by extracting one or more signal artifacts from a signal representing the frequency response of the conductivity probe to the alternating voltage applied thereto; and correlating the viral load in the medium with the one or more signal artifacts.

5 . The process of claim 4 , wherein correlating the viral load in the medium with the one or more signal artifacts comprises correlating the viral load in the medium with the one or more signal artifacts using a rule engine developed from a machine learning technique.

6 . The process of claim 1 , further comprising reducing or eliminating false positives and false negatives in the viral load determination using at least one of a particulate matter level, a carbon dioxide level, and the presence or absence of people in the airspace.

7 . The process of claim 1 , wherein:

the conductivity probe is a first conductivity probe;

the medium is a first medium;

the alternating voltage is a first alternating voltage;

the process further comprises:

providing a second conductivity probe;

applying a second alternating voltage to the second conductivity probe while the second conductivity probe is immersed at least in part in a second medium comprising the solvent;

determining a differential between the frequency response of the first conductivity probe to the alternating voltage applied thereto and a frequency response of the second conductivity probe to the alternating voltage applied thereto; and

determining the viral load in the first medium based on the frequency differential.

8 . The process of claim 7 , wherein the second medium is free of virus particles.

9 . The process of claim 7 , wherein determining the viral load in the first medium based on the frequency differential comprises determining the viral load in the first medium based on one of a homodyne and a heterodyne frequency detection technique.

10 . The process of claim 7 , wherein determining a viral load in the first medium based on the frequency differential comprises determining the viral load in the first medium based on a predetermined relationship between the viral load in the first medium and the frequency differential.

11 . The process of claim 7 , further comprising maintaining the first and second media at substantially the same temperature.

12 . The process of claim 1 , further comprising estimating the viral load in the airspace based on the viral load in the medium.

13 . The process of claim 12 , further comprising generating and sending a notification when the viral load in the airspace is determined to be greater than a predetermined value.

14 . The process of claim 1 , wherein separating particles from the air sample so that the particles become suspended in the solvent to form a medium comprises separating particles having an aerodynamic diameter of about ten microns or less from the air sample.

15 . The process of claim 1 , wherein determining a viral load in the medium based on a frequency response of the conductivity probe to the alternating voltage applied thereto comprises determining a viral load in the medium based on the frequency response of the conductivity probe to the alternating voltage applied thereto using an edge-cloud server.

16 . The process of claim 1 , further comprising:

measuring a temperature and a relative humidity of the airspace;

determining a particle concentration in the airspace; and

calculating a minimum separation distance needed to reduce a potential for human-to-human transmission of airborne pathogens, based on an estimate of distance the particles will travel upon being exhaled as determined using the temperature and relative humidity of the airspace, and the particle concentration in the airspace.

17 . The process of claim 1 , further comprising:

providing a tube in fluid communication with an interior of a chamber holding the solvent; and

breathing into the tube to introduce airborne virus particles into the solvent via the tube.

Priority Claims (1)
IN 202121004520 · Feb 2, 2021 · national
Continuity (3)
Continuation In Part 17461907 · Aug 30, 2021
Provisional Application 63119454 · Nov 30, 2020
Related Publication 20230152199A1 · May 18, 2023
References Cited (37)
US 4288544A · Suzuki · 1981 [cited by examiner]
US 5344535A · Betts · 1994 [cited by examiner]
US 8859297B2 · Alocilja et al. · 2014 [cited by applicant]
US 9424734B1 · Hagi et al. · 2016 [cited by applicant]
US 10327692B2 · Uchiyama · 2019 [cited by applicant]
US 20030186351A1 · Machida et al. · 2003 [cited by applicant]
US 20040239344A1 · Hu · 2004 [cited by applicant]
US 20050003396A1 · Ozkan et al. · 2005 [cited by applicant]
US 20120085927A1 · Maeng et al. · 2012 [cited by applicant]
US 20120225423A1 · Schwoebel et al. · 2012 [cited by applicant]
US 20120252003A1 · Schmera · 2012 [cited by examiner]
US 20150355133A1 · Prasad · 2015 [cited by applicant]
US 20160025677A1 · Chung et al. · 2016 [cited by applicant]
US 20170227486A1 · Bhansali et al. · 2017 [cited by applicant]
US 20190232282A1 · Pierson et al. · 2019 [cited by applicant]
US 20190250153A1 · Muthukumar et al. · 2019 [cited by applicant]
US 20200240939A1 · Prasad et al. · 2020 [cited by applicant]
US 20210239635A1 · Prasad et al. · 2021 [cited by applicant]
US 20210386317A1 · Prasad et al. · 2021 [cited by applicant]
US 20220018797A1 · Botte et al. · 2022 [cited by applicant]
US 20230408121A1 · Pal · 2023 [cited by examiner]
EP 2459984B1 · 2018 [cited by applicant]
IN 202021002188 · 2021 [cited by applicant]
KR 1020170096092A · 2017 [cited by applicant]
KR 101934946B1 · 2019 [cited by applicant]
WO WO2005031300A2 · 2005 [cited by applicant]
WO WO2007104058A2 · 2007 [cited by applicant]
WO WO2012047865A2 · 2012 [cited by applicant]
WO WO2019142599A1 · 2019 [cited by applicant]
ISR and Written Opinion of PCT/US0222/014873 dated May 23, 2022. [cited by applicant]
ISR and Written Opinion of PCT/US2021/061129 dated Mar. 18, 2022. [cited by applicant]
ISR and Written Opinion of PCT/US2021/048296 dated Dec. 21, 2021. [cited by applicant]
https://www.epa.gov/air-emissions-monitoring-knowledge-base/monitoring-control-technique-fabric-filters. [cited by applicant]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094991/. [cited by applicant]
https://www.epa.gov/pm-pollution/health-and-environmental-effects-particulate-matter-pm. [cited by applicant]
Alkhouri, et al., “Analysis of breath volatile organic compounds as a noninvasive tool to diagnose nonalcoholic fatty liver disease in children,” European journal of gastroenterology & hepatology, vol. 26, No. 1, pp. 82… [cited by applicant]
Alkhouri, et al.; “Isoprene in the Exhaled Breath is a Novel Biomarker for Advanced Fibrosis in Patients with Chronic Liver Disease: A Pilot Study Clinical and Translational Gastroenterology” 6(9):p. e112, Sep. 2015. | … [cited by applicant]
Cited By (1)
US 12,716,600